Table 2.
Examples of immune effects by histamine receptor-2 antagonists
Agent | Cell/whole animal | Response | Reference |
---|---|---|---|
Cimetidine | Guinea pigs | Increases activity of delayed type hypersensitivity and experimental autoimmune encephalomyelitis incidence | [25] |
Cimetidine | Mouse T cells | Inhibits induction of T suppressor cells | [45] |
Cimetidine | Mouse splenocytes | Increases antibody production, and proliferation of mitogen-activated splenocytes in response to tetanus toxoid | [51] |
Cimetidine | Mouse T cells | Inhibits regulatory T cell-like activity | [49] |
Cimetidine | Human T cells | Reduces suppressor T cell response | [46] |
Cimetidine | Human lymphocytes | Increases the mitogen-activated T cell response | [42,43] |
Cimetidine | Human DCs | Increases the capacity of antigen presentation by DCs from immunosuppressed cancer patients | [75] |
Ranitidine | Human T cells | Increases CD4+ T cells and mitogen-stimulated IFN-γ production from patients with head injury | [52] |
Ranitidine | Human monocytes, neutrophils, natural killer cells, delayed type hypersensitivity | Reverses surgery-induced immune suppression | [54,55] |
DC: dendritic cell; IFN-γ: interferon gamma.